- Home
- SRTS vs KLRS Comparison
SRTS vs KLRS Comparison
Compare SRTS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- KLRS
- Stock Information
- Founded
- SRTS 2010
- KLRS 2019
- Country
- SRTS United States
- KLRS United States
- Employees
- SRTS N/A
- KLRS N/A
- Industry
- SRTS Medical/Dental Instruments
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRTS Health Care
- KLRS Health Care
- Exchange
- SRTS Nasdaq
- KLRS Nasdaq
- Market Cap
- SRTS 51.8M
- KLRS 46.0M
- IPO Year
- SRTS 2016
- KLRS N/A
- Fundamental
- Price
- SRTS $3.45
- KLRS $6.59
- Analyst Decision
- SRTS Strong Buy
- KLRS Strong Buy
- Analyst Count
- SRTS 3
- KLRS 2
- Target Price
- SRTS $8.00
- KLRS $23.00
- AVG Volume (30 Days)
- SRTS 88.0K
- KLRS 232.2K
- Earning Date
- SRTS 11-13-2025
- KLRS 11-15-2025
- Dividend Yield
- SRTS N/A
- KLRS N/A
- EPS Growth
- SRTS N/A
- KLRS N/A
- EPS
- SRTS N/A
- KLRS N/A
- Revenue
- SRTS $37,564,000.00
- KLRS N/A
- Revenue This Year
- SRTS N/A
- KLRS N/A
- Revenue Next Year
- SRTS $46.14
- KLRS N/A
- P/E Ratio
- SRTS N/A
- KLRS N/A
- Revenue Growth
- SRTS 3.29
- KLRS N/A
- 52 Week Low
- SRTS $3.03
- KLRS $2.14
- 52 Week High
- SRTS $9.33
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- SRTS 56.63
- KLRS 67.51
- Support Level
- SRTS $3.11
- KLRS $4.41
- Resistance Level
- SRTS $3.68
- KLRS $8.80
- Average True Range (ATR)
- SRTS 0.12
- KLRS 0.89
- MACD
- SRTS 0.09
- KLRS 0.21
- Stochastic Oscillator
- SRTS 75.32
- KLRS 70.00
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.